Catalyst Pharmaceuticals, Inc. (CPRX): Price and Financial Metrics


Catalyst Pharmaceuticals, Inc. (CPRX): $4.60

0.07 (+1.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CPRX Stock Summary

  • CPRX's current price/earnings ratio is 6.27, which is higher than merely 4.93% of US stocks with positive earnings.
  • The ratio of debt to operating expenses for Catalyst Pharmaceuticals Inc is higher than it is for about only 0.3% of US stocks.
  • With a year-over-year growth in debt of -100%, Catalyst Pharmaceuticals Inc's debt growth rate surpasses merely 0% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Catalyst Pharmaceuticals Inc are AXTI, NTGR, NIU, FLDM, and ICAD.
  • CPRX's SEC filings can be seen here. And to visit Catalyst Pharmaceuticals Inc's official web site, go to www.catalystpharma.com.

CPRX Stock Price Chart Interactive Chart >

Price chart for CPRX

CPRX Price/Volume Stats

Current price $4.60 52-week high $5.19
Prev. close $4.53 52-week low $2.88
Day low $4.42 Volume 984,990
Day high $4.69 Avg. volume 1,687,284
50-day MA $4.22 Dividend yield N/A
200-day MA $3.77 Market Cap 477.60M

Catalyst Pharmaceuticals, Inc. (CPRX) Company Bio


Catalyst Pharmaceuticals focuses on the development and commercialization of prescription drugs targeting rare neurological diseases and disorders. The company was founded in 2002 and is based in Coral Gables, Florida.


CPRX Latest News Stream


Event/Time News Detail
Loading, please wait...

CPRX Latest Social Stream


Loading social stream, please wait...

View Full CPRX Social Stream

Latest CPRX News From Around the Web

Below are the latest news stories about Catalyst Pharmaceuticals Inc that investors may wish to consider to help them evaluate CPRX as an investment opportunity.

Catalyst Pharma To Buy Back $40M In Stock; Shares Gain Pre-Market

Shares of Catalyst Pharma rose more than 3% in the pre-market session after the commercial-stage biopharmaceutical company announced its stock repurchase program of up to $40 million. Catalyst Pharma (CPRX) intends to use existing cash on hand to fund the share repurchase program. Catalyst Pharma CEO Patrick J. McEnany said, “We believe that our strong balance sheet, earnings power and borrowing capability have us well-positioned to successfully execute both on our recently announced strategic initiative to expand our product and pipeline portfolio of therapies to treat other rare diseases and on this share repurchase program.” (See Catalyst Pharma stock analysis on TipRanks) Last week, the company reported 4Q results.

Priti Ramgarhia on TipRanks | March 22, 2021

With EPS Growth And More, Catalyst Pharmaceuticals (NASDAQ:CPRX) Is Interesting

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...

Yahoo | March 21, 2021

Top Biotech Stocks for Q2 2021

The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline.

Yahoo | March 18, 2021

Catalyst Pharma 4Q Revenue, Earnings Outperform Estimates

Catalyst Pharmaceuticals delivered a better-than-expected 4Q performance, driven by higher sales for Firdapse, which is used to treat Lambert-Eaton myasthenic syndrome (LEMS) patients. Shares of the commercial stage biopharmaceutical company rose about 1.5% in the extended trading session on Monday. Catalyst Pharma’s (CPRX) revenue, comprised primarily of Firdapse sales, increased by $0.9 million year-over-year to hit $31 million, topping analysts’ estimates of $30.35 million. The company posted adjusted earnings of $0.11 per share, up 57% year-over-year, with the figure exceeding analysts’ expectations of $0.09 per share. The company’s Chairman and CEO Patrick J. McEnany said, “We are extremely pleased with our continued commercial execution of the Firdapse launch during 2020.

Kailas Salunkhe on TipRanks | March 16, 2021

Catalyst Pharmaceuticals, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 16, 2021 / Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 16, 2021 at 8:30 AM Eastern Time.

Yahoo | March 16, 2021

Read More 'CPRX' Stories Here

CPRX Price Returns

1-mo -1.50%
3-mo 27.78%
6-mo 44.20%
1-year -3.97%
3-year 79.69%
5-year 280.17%
YTD 37.72%
2020 -10.93%
2019 95.31%
2018 -50.90%
2017 272.38%
2016 -57.14%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.0335 seconds.